Pazenir (paclitaxel) – to treat adults patients with metastatic breast cancer and non-small cell lung cancer.

Pazenir is used to treat the following cancers in adults:

  • metastatic breast cancer, when the first treatment has stopped working and standard treatment including an ‘anthracycline’ (another type of cancer medicine) is not suitable. ‘Metastatic’ means that the cancer has spread to other parts of the body;
  • non-small cell lung cancer, as a first treatment in combination with the cancer medicine carboplatin when the patient cannot have surgery or radiotherapy.

 

NAME OF THE MEDICINAL PRODUCT

Pazenir 5 mg/ml powder for dispersion for infusion.

QUALITATIVE AND QUANTITATIVE COMPOSITION

Each vial contains 100 mg of paclitaxel formulated as albumin bound nanoparticles.
After reconstitution, each ml of dispersion contains 5 mg of paclitaxel formulated as albumin bound nanoparticles.

Excipients with known effect 

Each ml of concentrate contains 0.183 mmol sodium, which is 4.2 mg of sodium.

PHARMACEUTICAL FORM

Powder for dispersion for infusion.
The reconstituted dispersion has a pH of 6-7.5 and an osmolality of 300-360 mOsm/kg. The powder is white to yellow.

 

METHOD AND ROUTE(S) OF ADMINISTRATION

Intravenous use.

BACK